Sunshine Biopharma Inc (NASDAQ:SBFM) price on current trading day, rose 3.41% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $3.34.
A look at the stock’s price movement, the close in the last trading session was $3.23, moving within a range at $3.12 and $3.43. The beta value (5-Year monthly) was -1.036. Turning to its 52-week performance, $608.00 and $2.11 were the 52-week high and 52-week low respectively. Overall, SBFM moved 24.63% over the past month.
Sunshine Biopharma Inc’s market cap currently stands at around $6.68 million, with investors looking forward to this quarter’s earnings report slated for in January.
Analysts have a consensus estimate of 12.5M for the company’s revenue for the quarter, with a low and high estimate of 12.5M and 12.5M respectively. The average forecast suggests up to a 62.76% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 27.78M, representing a 15.30% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that SBFM is a 50% Sell. On the other hand, the stock is on average a 50% Sell as suggested by medium term indicators while long term indicators are putting the stock in 50% Sell category.
SBFM’s current price about 25.72% and 17.29% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 63.11, while 7-day volatility ratio is 12.76% and 12.20% in the 30-day chart. Further, Sunshine Biopharma Inc (SBFM) has a beta value of -0.95, and an average true range (ATR) of 0.31.
If we refocus on Sunshine Biopharma Inc (NASDAQ:SBFM), historical trading data shows that trading volumes averaged 3.5 over the past 10 days and 703.14K over the past 3 months. The company’s latest data on shares outstanding shows there are 2.00 million shares.
The 0.10% of Sunshine Biopharma Inc’s shares are in the hands of company insiders while institutional holders own 1.98% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 0.23 million on 2024-11-15, giving us a short ratio of 1.71. The data shows that as of 2024-11-15 short interest in Sunshine Biopharma Inc (SBFM) stood at 1172.0 of shares outstanding, with shares short falling to 0.32 million registered in 2024-10-15. Current price change has pushed the stock -99.38% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the SBFM stock continues to rise going into the next quarter.
